Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.

Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.